• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by MISONIX, Inc.

    10/29/21 10:27:53 AM ET
    $MSON
    Medical Specialities
    Capital Goods
    Get the next $MSON alert in real time by email
    S-8 POS 1 d206544ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on October 29, 2021

    Registration No. 33-73924

    333-18907

    333-78795

    333-63166

    333-130874

    333-165088

    333-188554

    333-203944

    333-219348

    333-248581

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 (NO. 33-73924)

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 (NO. 333-18907)

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 (NO. 333-78795)

    POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 (NO. 333-63166)

    POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 (NO. 333-130874)

    POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 (NO. 333-165088)

    POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 (NO. 333-188554)

    POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 (NO. 333-203944)

    POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-8 (NO. 333-219348)

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 (NO. 333-248581)

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Misonix, Inc.

    (By Misonix, LLC, as successor by merger to Misonix, Inc.)

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   84-1856018

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    c/o Bioventus Inc.

    1938 New Highway

    Farmingdale, NY 11735

      11735
    (Address of principal executive offices)   (Zip code)

     

     

    Stock Option Plan

    1996 Employee Incentive Stock Option Plan

    1996 Non-Employee Director Stock Option Plan

    1998 Employee Stock Option Plan

    2001 Employee Stock Option Plan

    2005 Employee Equity Incentive Plan

    2005 Non-Employee Director Stock Option Plan

    Misonix, Inc. 2009 Employee Equity Incentive Plan

    Misonix, Inc. 2009 Non-Employee Director Stock Option Plan

    Misonix, Inc. 2012 Employee Equity Incentive Plan

    Misonix, Inc. 2012 Non-Employee Director Stock Option Plan

    Misonix, Inc. 2014 Employee Equity Incentive Plan

    Misonix, Inc. 2017 Equity Incentive Plan

    (Full title of the plans)

     

     

    Kenneth M. Reali

    Chief Executive Officer

    c/o Bioventus Inc.

    4721 Emperor Boulevard, Suite 100

    Durham, North Carolina 27703

    Telephone: (919) 474-6700

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

     

    Wesley C. Holmes

    Mark M. Bekheit

    Latham & Watkins LLP

    140 Scott Drive

    Menlo Park, California 94025

    (650) 328-4600

     

    Jonn R. Beeson, Esq.

    Jones Day

    3161 Michelson Drive, Suite 800

    Irvine, California 92612

    (949) 553-7528

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    DEREGISTRATION OF SECURITIES

    On July 29, 2021, Misonix, Inc., a Delaware corporation (“Registrant”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Bioventus Inc., a Delaware corporation (“Bioventus”), Oyster Merger Sub I, Inc. (“Merger Sub I”), a wholly owned subsidiary of Bioventus, and Oyster Merger Sub II, LLC (“Merger Sub II”), a wholly owned subsidiary of Bioventus. Pursuant to the Merger Agreement, effective October 29, 2021, Bioventus acquired Registrant through a merger of Merger Sub I with and into Registrant, with Registrant continuing as the surviving corporation (the “First Merger”), followed by a merger of Registrant with and into Merger Sub II, with Merger Sub II continuing as the surviving entity and a wholly owned subsidiary of Bioventus under the name “Misonix, LLC” (the “Second Merger,” and, together with the First Merger, the “Mergers”). This Post-Effective Amendment (the “Post-Effective Amendment”), filed by Misonix, LLC (as successor by merger to Registrant), withdraws and removes from registration all unissued shares of common stock, par value $0.0001 per share, of Misonix, Inc. (such common stock, “Common Stock”), under the following Registration Statements on Form S-8 (each, a “Registration Statement” and, collectively, the “Registration Statements”) filed with the U.S. Securities and Exchange Commission (the “SEC”), together with any and all plan interests and any other securities registered thereunder, without giving effect to any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increased the number of outstanding shares of Common Stock:

     

      •  

    Registration Statement on Form S-8 (No. 33-73924), filed with the SEC on January 7, 1994, pertaining to the registration of 250,000 shares of common stock, $0.01 par value per share, of Misonix OpCo, Inc., a New York corporation (f/k/a Misonix, Inc.) (such common stock, “Predecessor Common Stock”) reserved for issuance under the Stock Option Plan;

     

      •  

    Registration Statement on Form S-8 (No. 333-18907), filed with the SEC on March 21, 1997, pertaining to the registration of 1,050,000 shares of Predecessor Common Stock, reserved for issuance under the 1996 Employee Incentive Stock Option Plan and 1996 Non-Employee Incentive Stock Option Plan;

     

      •  

    Registration Statement on Form S-8 (No. 333-78795), filed with the SEC on May 19, 1999, pertaining to the registration of 500,000 shares of Predecessor Common Stock, reserved for issuance under 1998 Employee Stock Option Plan;

     

      •  

    Registration Statement on Form S-8 (No. 333-63166), filed with the SEC on June 15, 2001, pertaining to the registration of 1,000,000 shares of Predecessor Common Stock, reserved for issuance under 2001 Employee Stock Option Plan;

     

      •  

    Registration Statement on Form S-8 (No. 333-130874), filed with the SEC on January 5, 2006, pertaining to the registration of 700,000 shares of Predecessor Common Stock, reserved for issuance under 2005 Employee Equity Incentive Plan and 2005 Non-Employee Director Stock Option Plan;

     

      •  

    Registration Statement on Form S-8 (No. 333-165088), filed with the SEC on February 26, 2010, pertaining to the registration of 700,000 shares of Predecessor Common Stock, reserved for issuance under Misonix, Inc. 2009 Employee Equity Incentive Plan and Misonix, Inc. 2009 Non-Employee Director Stock Option Plan;


      •  

    Registration Statement on Form S-8 (No. 333-188554), filed with the SEC on May 13, 2013, pertaining to the registration of 700,000 shares of Predecessor Common Stock, reserved for issuance under Misonix, Inc. 2012 Employee Equity Incentive Plan and Misonix, Inc. 2012 Non-Employee Director Stock Option Plan;

     

      •  

    Registration Statement on Form S-8 (No. 333-203944), filed with the SEC on May 7, 2015, pertaining to the registration of 750,000 shares of Predecessor Common Stock, reserved for issuance under Misonix, Inc. 2014 Employee Equity Incentive Plan;

     

      •  

    Registration Statement on Form S-8 (No. 333-219348), filed with the SEC on July 19, 2017, pertaining to the registration of 750,000 shares of Predecessor Common Stock, reserved for issuance under Misonix, Inc. 2017 Employee Equity Incentive Plan; and

     

      •  

    Registration Statement on Form S-8 (No. 333- 248581), filed with the SEC on September 3, 2020, pertaining to the registration of 1,200,000 shares of Common Stock, reserved for issuance under Misonix, Inc. 2017 Employee Equity Incentive Plan, as amended.

    As a result of the Mergers, Registrant has terminated any and all offerings of Registrant’s securities pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. In accordance with undertakings made in the Registration Statements to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold or unissued at the termination of the offering, Registrant hereby removes from registration all such securities of Registrant registered pursuant to the Registration Statements that remain unsold or unissued as of the date hereof. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on this 29th day of October, 2021.

     

    Misonix, LLC (as successor by merger to

    Misonix, Inc.)

    By:   /s/ Kenneth M. Reali
    Name: Kenneth M. Reali
    Title:   Chief Executive Officer

    No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.

    Get the next $MSON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MSON

    DatePrice TargetRatingAnalyst
    8/2/2021Buy → Neutral
    BTIG
    7/30/2021$23.00 → $28.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $MSON
    SEC Filings

    View All

    SEC Form RW filed by MISONIX, Inc.

    RW - MISONIX INC (0000880432) (Filer)

    11/22/21 4:16:00 PM ET
    $MSON
    Medical Specialities
    Capital Goods

    SEC Form 15-12B filed by MISONIX, Inc.

    15-12B - MISONIX INC (0000880432) (Filer)

    11/8/21 4:30:57 PM ET
    $MSON
    Medical Specialities
    Capital Goods

    MISONIX, Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits

    8-K - MISONIX INC (0000880432) (Filer)

    10/29/21 4:50:05 PM ET
    $MSON
    Medical Specialities
    Capital Goods

    $MSON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Misonix downgraded by BTIG

    BTIG downgraded Misonix from Buy to Neutral

    8/2/21 5:49:45 AM ET
    $MSON
    Medical Specialities
    Capital Goods

    Misonix downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Misonix from Buy to Hold and set a new price target of $28.00 from $23.00 previously

    7/30/21 6:33:04 AM ET
    $MSON
    Medical Specialities
    Capital Goods

    $MSON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Koby Michael returned 1,744,017 shares to the company

    4 - MISONIX INC (0000880432) (Issuer)

    12/8/21 5:01:08 PM ET
    $MSON
    Medical Specialities
    Capital Goods

    SEC Form 4: Vizirgianakis Stavros G. returned 2,136,478 shares to the company, closing all direct ownership in the company

    4 - MISONIX INC (0000880432) (Issuer)

    12/8/21 4:56:38 PM ET
    $MSON
    Medical Specialities
    Capital Goods

    SEC Form 4: Patton Thomas M returned 104,500 shares to the company, closing all direct ownership in the company

    4 - MISONIX INC (0000880432) (Issuer)

    12/8/21 4:53:29 PM ET
    $MSON
    Medical Specialities
    Capital Goods

    $MSON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus

    DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, and Misonix, Inc. (NASDAQ:MSON) ("Misonix"), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that the stockholders of Bioventus approved the issuance of shares of Bioventus class A common stock to the stockholders of Misonix in connection with the previously announced Agreement and Plan of Merger, dated July 29, 2021, by and among Bioventus, Misonix and other parties thereto, pursuant to which Misonix will be acquired

    10/26/21 4:15:00 PM ET
    $BVS
    $MSON
    Medical/Dental Instruments
    Health Care
    Medical Specialities
    Capital Goods

    BIOVENTUS INC. and MISONIX, INC. Announce Election Deadline of 5:00 p.m. New York City Time, on October 25, 2021 for Misonix Stockholders to Elect Form of Merger Consideration

    DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) and Misonix, Inc. (NASDAQ:MSON) ("Misonix"), today announced an election deadline of 5:00 p.m., New York City Time, on October 25, 2021 (the "Election Deadline") for stockholders of Misonix to elect the form of consideration they wish to receive for their shares of Misonix common stock in connection with the proposed merger of Oyster Merger Sub I, Inc., a newly-formed, wholly-owned subsidiary of Bioventus ("Merger Sub I"), with and into Misonix, immediately followed by the merger of Misonix with and into Oyster Merger Sub II, LLC, another newly-formed, wholly-owned subsidiary of Bioventus ("Me

    10/18/21 8:00:00 AM ET
    $BVS
    $MSON
    Medical/Dental Instruments
    Health Care
    Medical Specialities
    Capital Goods

    Misonix Reports Fourth Quarter and Fiscal Year 2021 Financial Results

    FARMINGDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021 as summarized below:  Three Months Ended Years Ended  June 30, June 30,   2021   2020   2021  2020          Revenue$19,685,141  $13,713,231  $74,024,073 $62,483,651  Gross profit$14,075,377  $9,432,383  $52,636,255 $43,709,483  Gross profit percentage 71.5%  68.8%  71.1% 70.0% Pretax loss$(4,341,201) $(8,495,994) $(14,341,254)$(21,91

    9/2/21 4:01:00 PM ET
    $BVS
    $MSON
    Medical/Dental Instruments
    Health Care
    Medical Specialities
    Capital Goods

    $MSON
    Leadership Updates

    Live Leadership Updates

    View All

    Misonix Appoints Patrick J. Beyer to Board of Directors

    FARMINGDALE, N.Y., May 14, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced its Board of Directors has appointed Patrick J. Beyer as an independent member of the Board. Mr. Beyer joined the Board on May 12, 2021. "Pat is a highly respected, purpose-driven leader who has a proven, long-term track record of success throughout his career in the healthcare industry," stated Stavros Vizirgianakis, Chief Executive Officer of Misonix. "Pat has been an integral member of ConMed's executive team and his leadership expert

    5/14/21 8:30:00 AM ET
    $MSON
    Medical Specialities
    Capital Goods

    $MSON
    Financials

    Live finance-specific insights

    View All

    Misonix Reports Fourth Quarter and Fiscal Year 2021 Financial Results

    FARMINGDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021 as summarized below:  Three Months Ended Years Ended  June 30, June 30,   2021   2020   2021  2020          Revenue$19,685,141  $13,713,231  $74,024,073 $62,483,651  Gross profit$14,075,377  $9,432,383  $52,636,255 $43,709,483  Gross profit percentage 71.5%  68.8%  71.1% 70.0% Pretax loss$(4,341,201) $(8,495,994) $(14,341,254)$(21,91

    9/2/21 4:01:00 PM ET
    $BVS
    $MSON
    Medical/Dental Instruments
    Health Care
    Medical Specialities
    Capital Goods

    Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix

    Significantly Expands TAM and Adds Considerable Scale and Scope in Spine and Lower ExtremityEnhances Surgical Solutions Vertical by Adding Minimally Invasive Ultrasonic Technologies That Improve Clinical OutcomesDeepens Restorative Therapies Vertical by Adding Regenerative Medicine Wound ProductsBioventus and Misonix Management to Host Joint Conference Call Today at 4:30 p.m. Eastern Time DURHAM, N.C. and FARMINGDALE, N.Y., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus"), a global leader in innovations for active healing, and Misonix, Inc. (NASDAQ:MSON) ("Misonix"), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine

    7/29/21 4:05:00 PM ET
    $MSON
    $BVS
    Medical Specialities
    Capital Goods
    Medical/Dental Instruments
    Health Care

    Bioventus Inc. Reports Preliminary Second Quarter Net Sales; Updates Full-Year 2021 Net Sales Guidance

    DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported preliminary financial results for the three months ended July 3, 2021. Preliminary Second Quarter Net Sales: Net Sales of $108 million to $110 million represents 86.2% to 89.7% year-over-year growth and comprises: Net sales from legacy Bioventus Inc. of $96.5 million to $98.0 million, representing organic year-over-year revenue growth* of 66.4% to 69.0%, andNet sales from the acquisition of Bioness Inc. of $11.5 million to $12.0 million. Updated Full-Year 2021 Net Sales Guidance: For the twelve

    7/29/21 4:00:00 PM ET
    $MSON
    $BVS
    Medical Specialities
    Capital Goods
    Medical/Dental Instruments
    Health Care

    $MSON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - MISONIX INC (0000880432) (Subject)

    2/16/21 4:01:08 PM ET
    $MSON
    Medical Specialities
    Capital Goods

    SEC Form SC 13G/A filed

    SC 13G/A - MISONIX INC (0000880432) (Subject)

    2/5/21 4:48:17 PM ET
    $MSON
    Medical Specialities
    Capital Goods